866-997-4948(US-Canada Toll Free)

Pancreatic Tumor Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Nov 2012

Category :

Oncology

No. of Pages : 67 Pages


Pancreatic Tumor Pipeline Review, H2 2012

Summary

Global Markets Directs, 'Pancreatic Tumor Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Pancreatic Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pancreatic Tumor. Pancreatic Tumor Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Pancreatic Tumor.
  • A review of the Pancreatic Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Pancreatic Tumor pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Pancreatic Tumor.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Pancreatic Tumor pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Pancreatic Tumor Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Pancreatic Tumor 8
Pancreatic Tumor Therapeutics under Development by Companies 10
Pancreatic Tumor Therapeutics under Investigation by Universities/Institutes 11
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Pancreatic Tumor Therapeutics Products under Development by Companies 16
Pancreatic Tumor Therapeutics Products under Investigation by Universities/Institutes 17
Companies Involved in Pancreatic Tumor Therapeutics Development 18
Eli Lilly and Company 18
Novartis AG 19
Threshold Pharmaceuticals, Inc. 20
Pancreatic Tumor Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
BEZ-235 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Bevacizumab + Temozolomide - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
AMG 706 + Octreotide - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Temsirolimus + Bevacizumab - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
FOLFIRI - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Paclitaxel + Carboplatin + Etoposide - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Thalidomide + Temodar - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
IMC-A12 + Octreotide - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
TH-302 + Sunitinib - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Bevacizumab + Pertuzumab + Sandostatin - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Temsirolimus + Vinorelbine Ditartrate - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Everolimus + Octreotide - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Everolimus + Octreotide + Bevacizumab - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
X-82 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Pasireotide + Everolimus - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
VCN-01 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
BYL-719 + MEK-162 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
cabozantinib - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Capecitabine + Temozolomide + Bevacizumab - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
TH-302 + Radiation Therapy - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Pancreatic Tumor Therapeutics Drug Profile Updates 55
Pancreatic Tumor Therapeutics - Dormant Products 57
Pancreatic Tumor Product Development Milestones 58
Featured News & Press Releases 58
Jun 19, 2012: Combination Of TH-302 And Radiation Reduces Human Pancreatic Tumor Growth In Hypoxic Xenografts, Study Finds 58
Nov 07, 2011: Pfizer Files Application For Additional Indication Of Sutent In Japan 58
Jul 22, 2011: Novartis Drug Afinitor Recommended By CHMP For EU Approval To Treat Patients With Advanced Pancreatic Neuroendocrine Tumors 59
Jun 15, 2011: VCN Biosciences Obtains Orphan Drug Designation From European Medicines Agency (EMA) To Their Candidate VCN-01 In The Treatment Of Human Exocrine Pancreatic Tumors 60
May 20, 2011: SUTENT Receives FDA Approval For Advanced Pancreatic Neuroendocrine Tumors 60
May 05, 2011: Novartis's Afinitor Gains FDA Approval As First New Treatment For Patients With Advanced Pancreatic Neuroendocrine Tumors 61
Apr 12, 2011: FDA's Panel Recommends Approval of Novartis's Afinitor For Treatment Of Advanced Neuroendocrine Tumors 62
Apr 12, 2011: Pfizer's SUTENT Receives Favorable Review From FDA Panel 63
Jan 22, 2010: Pfizer Announces Phase III Trial Results Of Sutent 64

Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 67
Disclaimer 67

List of Table


Number of Products Under Development for Pancreatic Tumor, H2 2012 8
Products under Development for Pancreatic Tumor Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
Eli Lilly and Company, H2 2012 18
Novartis AG, H2 2012 19
Threshold Pharmaceuticals, Inc., H2 2012 20
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Pancreatic Tumor Therapeutics Drug Profile Updates 55
Pancreatic Tumor Therapeutics Dormant Products 57

List of Chart


Number of Products under Development for Pancreatic Tumor, H2 2012 8
Products under Development for Pancreatic Tumor Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *